Adamis Pharmaceuticals: Still No Love After Uplisting To Nasdaq
- The steep 3-day sell-off is unfounded, overdone and misunderstood.
- 8-drug pipeline with 4 of them in late-stage development.
- Short-term catalysts are current valuation, NDA filing this month for Epinephrine PFS (Epi Pen) and upcoming clinical trials this summer for their Dry Powder Inhaler (APC-5000).
- Adamis has now fully acquired 3M's Taper Dry Powder Inhaler (DPI) Technology.